BeOne Medicines registers Phase 1 drug interaction trial for CDK4 inhibitor BGB-43395

BeOne Medicines has one trial update this week involving its CDK4 inhibitor candidate.

• A Phase 1, open-label trial (NCT07820891) is recruiting to evaluate drug interactions between BGB-43395, a drug that blocks cyclin-dependent kinase 4 and is being developed for patients with advanced solid tumors¹, and a cocktail of marker drugs. The study will test whether BGB-43395 has any significant drug interactions with midazolam, celecoxib, dabigatran, and rosuvastatin¹, with approximately 24 healthy adult participants enrolled¹. The trial's actual start date is listed as September 25, 2026, with an estimated primary completion of November 22, 2026, and BeOne Medicines is sponsoring the study with Fortrea as a collaborator.